Skip to main content
Erschienen in: Cancer Causes & Control 3/2013

01.03.2013 | Original paper

Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women

verfasst von: Juhua Luo, Rowan Chlebowski, Simin Liu, Katherine A. McGlynn, Niyati Parekh, Donna L. White, Karen L. Margolis

Erschienen in: Cancer Causes & Control | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

While diabetes has been linked to several cancers in the gastrointestinal (GI) tract, findings have been mixed for sites other than colorectal and liver cancer. We used the Women’s Health Initiative (WHI) data and conducted a comprehensive assessment of associations between diabetes and GI malignancy (esophagus, stomach, liver, biliary, pancreas, colon, and rectal).

Methods

A total of 145,765 postmenopausal women aged 50–79 enrolled in the WHI were followed for a mean 10.3 years. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for the association between GI cancers and diagnosed diabetes, including its duration and treatment.

Results

Diabetes at enrollment was associated with increased risk of liver (HR = 2.97; 95 % CI, 1.66–5.32), pancreatic (HR = 1.62; 95 % CI, 1.15–2.30), colon (HR = 1.38; 95 % CI, 1.14–1.66), and rectal (HR = 1.87, 95 % CI: 1.22–2.85) cancer. Diabetes severity, assessed by duration or need for pharmacotherapy, appeared to have stronger links to risk of liver, pancreatic, and rectal cancer, but not colon cancer. There was no statistically significant association of diabetes with biliary, esophageal, and stomach cancers.

Conclusion

Type 2 diabetes is associated with a significantly increased risk of cancers of the liver, pancreas, colon, and rectum in postmenopausal women. The suggestion that diabetes severity further increases these cancer risks requires future studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W (2003) Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 362:537–538PubMedCrossRef Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W (2003) Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 362:537–538PubMedCrossRef
2.
Zurück zum Zitat Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685PubMedCrossRef Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674–1685PubMedCrossRef
3.
Zurück zum Zitat Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841 Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841
4.
Zurück zum Zitat Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928PubMedCrossRef Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928PubMedCrossRef
5.
Zurück zum Zitat Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef
6.
Zurück zum Zitat Berster JM, Goke B (2008) Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114:84–98PubMedCrossRef Berster JM, Goke B (2008) Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 114:84–98PubMedCrossRef
7.
Zurück zum Zitat Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef
8.
Zurück zum Zitat El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRef El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380PubMedCrossRef
9.
Zurück zum Zitat Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938–1946 Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116:1938–1946
10.
Zurück zum Zitat Grote VA, Becker S, Kaaks R (2011) Diabetes mellitus type 2—an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 118:4–8CrossRef Grote VA, Becker S, Kaaks R (2011) Diabetes mellitus type 2—an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 118:4–8CrossRef
11.
Zurück zum Zitat Adami HO, Chow WH, Nyren O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472–1477PubMedCrossRef Adami HO, Chow WH, Nyren O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472–1477PubMedCrossRef
12.
Zurück zum Zitat Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ (2009) Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroentrol 15:5274–5278CrossRef Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ (2009) Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroentrol 15:5274–5278CrossRef
13.
Zurück zum Zitat Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2010) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128:635–643CrossRef Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2010) Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 128:635–643CrossRef
14.
Zurück zum Zitat Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877PubMedCrossRef Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877PubMedCrossRef
15.
Zurück zum Zitat La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 73:204–207PubMedCrossRef La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 73:204–207PubMedCrossRef
16.
Zurück zum Zitat La Vecchia C, Negri E, Decarli A, Franceschi S (1998) Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 19:61–109CrossRef La Vecchia C, Negri E, Decarli A, Franceschi S (1998) Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 19:61–109CrossRef
17.
Zurück zum Zitat Hays J, Hunt JR, Hubbell FA et al (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77PubMedCrossRef Hays J, Hunt JR, Hubbell FA et al (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13:S18–S77PubMedCrossRef
18.
Zurück zum Zitat Jackson RD, LaCroix AZ, Cauley JA, McGowan J (2003) The Women’s Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S98–S106PubMedCrossRef Jackson RD, LaCroix AZ, Cauley JA, McGowan J (2003) The Women’s Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S98–S106PubMedCrossRef
19.
Zurück zum Zitat Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13:S107–S121PubMedCrossRef Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13:S107–S121PubMedCrossRef
20.
Zurück zum Zitat Ritenbaugh C, Patterson RE, Chlebowski RT et al (2003) The Women’s Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S87–S97PubMedCrossRef Ritenbaugh C, Patterson RE, Chlebowski RT et al (2003) The Women’s Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol 13:S87–S97PubMedCrossRef
21.
Zurück zum Zitat Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR (2003) The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13:S78–S86PubMedCrossRef Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR (2003) The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13:S78–S86PubMedCrossRef
22.
Zurück zum Zitat Margolis KL, Lihong Q, Brzyski R et al (2008) Validity of diabetes self-reports in the Women’s Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 5:240–247PubMedCrossRef Margolis KL, Lihong Q, Brzyski R et al (2008) Validity of diabetes self-reports in the Women’s Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 5:240–247PubMedCrossRef
23.
Zurück zum Zitat Jackson JM, DeFor TA, Crain AL, et al. Validity of diabetes self-reports in the Women’s Health Initiative. J Clin Epi (in press) Jackson JM, DeFor TA, Crain AL, et al. Validity of diabetes self-reports in the Women’s Health Initiative. J Clin Epi (in press)
24.
Zurück zum Zitat Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in cox regression. Stat Med 14:1707–1723PubMedCrossRef Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in cox regression. Stat Med 14:1707–1723PubMedCrossRef
25.
Zurück zum Zitat Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114:63–70PubMedCrossRef Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114:63–70PubMedCrossRef
26.
Zurück zum Zitat Walker A (1991) Observation and inference. An introduction to the methods of epidemiology. Epidemiology Resources Inc., USA Walker A (1991) Observation and inference. An introduction to the methods of epidemiology. Epidemiology Resources Inc., USA
27.
Zurück zum Zitat Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G (1994) Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19:616–627PubMedCrossRef Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G (1994) Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19:616–627PubMedCrossRef
28.
Zurück zum Zitat Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356–1362PubMedCrossRef Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356–1362PubMedCrossRef
29.
Zurück zum Zitat Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106–1110PubMedCrossRef Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106–1110PubMedCrossRef
30.
Zurück zum Zitat Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y (2001) Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51:127–131PubMedCrossRef Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y (2001) Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51:127–131PubMedCrossRef
31.
Zurück zum Zitat Davila JA (2010) Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors? Am J Gastroenterol 105:632–634PubMedCrossRef Davila JA (2010) Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors? Am J Gastroenterol 105:632–634PubMedCrossRef
32.
Zurück zum Zitat Sanyal A, Poklepovic A, Moyneur E, Barghout V Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 26:2183–2191 Sanyal A, Poklepovic A, Moyneur E, Barghout V Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 26:2183–2191
33.
Zurück zum Zitat Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A (2000) Abnormal glucose metabolism and pancreatic cancer mortality. Jama-J Am Med Assoc 283:2552–2558CrossRef Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A (2000) Abnormal glucose metabolism and pancreatic cancer mortality. Jama-J Am Med Assoc 283:2552–2558CrossRef
34.
Zurück zum Zitat Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365PubMedCrossRef Wideroff L, Gridley G, Mellemkjaer L et al (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365PubMedCrossRef
35.
Zurück zum Zitat Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef
36.
Zurück zum Zitat Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777PubMedCrossRef Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777PubMedCrossRef
37.
Zurück zum Zitat Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625PubMedCrossRef Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625PubMedCrossRef
38.
Zurück zum Zitat Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef
Metadaten
Titel
Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women
verfasst von
Juhua Luo
Rowan Chlebowski
Simin Liu
Katherine A. McGlynn
Niyati Parekh
Donna L. White
Karen L. Margolis
Publikationsdatum
01.03.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 3/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-9996-8

Weitere Artikel der Ausgabe 3/2013

Cancer Causes & Control 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.